should be paid to the period of time for which medicines are dispensed. Apprxomately one in five medicines are eligible for redispensing and this could help to prevent waste. WASTE OF ORAL ONCOLYTICS AND BIOLOGICALS AMONG USERS WHO DISCONTINUE THERAPY Charlotte L. Bekker MSc a,b , Helga Gardarsdottir PhD b, c , Eward Melis MSc b , Toine C.G. Egberts, Professor of Clinical Pharmacy b, c , Marcel L. Bouvy, Professor of Pharmaceutical Care c , Bart J.F. van den Bemt PhD/PharmD a, d . a Sint Maartenskliniek, Netherlands; b University Medical Centre Utrecht, Netherlands; c Utrecht University, Netherlands; d Radboud University Medical Centre, Netherlands E-mail addresses: c.bekker@maartenskliniek.nl (C.L. Bekker), h.gardarsdottir@ umcutrecht.nl (H. Gardarsdottir), e.j.melis-2@umcutrecht.nl (E. Melis), a.c.g. egberts@umcutrecht.nl (M.L. Egberts), m.l.bouvy@uu.nl (M.L. Bouvy), b.vanden- bemt@maartenskliniek.nl (B.J.F. van den Bemt). Introduction: Oral oncolytics and biological DMARDs (bDMARDs) are costly therapies. An estimated one out of four users stops their therapy early, which may lead to medication waste if medicines are already taken from the pharmacy but left unused. To avoid this waste, the unused medicines that are still of good quality could be redispensed to another patient. Objectives: To examine the proportion of oral oncolytics and bDMARDs users who stop therapy and have medicines left over, the related medicine costs, and the proportion of users with unused medicines that could theoretically be redispensed. Methods: Patients who had stopped using their oral oncolytic or bDMARD, as prescribed by a medical specialist, from November 2015 to March 2016 were identified in a Dutch academic hospital outpatient pharmacy from the electronic pharmacy information system. This sys- tem shows the dispensing date, the amount prescribed and the daily dose for each medicine by which a date could be calculated that in- dicates when the patient would be in need of a refill. Patients receiving no refill of the medicine were selected. Patients were approached by phone and after consenting directly interviewed about the amount of medicines that was left unused including the number of unopened packs. Medicines were defined as suitable for redispensing when con- tained in unopened packs and not used at all. Costs of leftover medicines were determined using Dutch medicine prices. Data were descriptively analysed. Results: 1483 oral oncolytic users were included of which 29 patients (2%) had stopped therapy and medicines leftover. Of them, 12 patients (<1% of total) had unused packs that were suitable for redispensing, with a total cost of around V29.730. 804 bDMARD users were included of which 19 patients (2.4%) had stopped therapy and medicines leftover. Of them, 12 patients (1.5%) had unused packs that were suitable for redispensing, with a total cost of around V18.900. Discussion and Conclusions: Few patients who stop oral oncolytics and bDMARDs therapy have unused medicines leftover. Even less patients, around one per cent, receiving those medicines has medicines that could theoretically be redispensed, but as these are very expensive, nation-wide millions of euros spent on unused medicines are wasted. It might therefore be interesting to redispense those medicines or to dispense them in smaller amounts. ADHD, MEDICINE, AND POWER: PERSONAL EXPERIENCES IN A FOUCAULDIAN PERSPECTIVE Louise C. Druedahl MSc. Pharm, SofiaK€ alvemark Sporrong PhD. University of Copenhagen, Denmark E-mail addresses: louise.druedahl@sund.ku.dk (L.C. Druedahl), sofia.sporrong@sund. ku.dk (S.K. Sporrong). Introduction: Attention-deficit hyperactivity disorder (ADHD) is a disor- der describing difficulties in hyperactivity, inattention, and impulsivity. It is very present and much debated in Denmark. According to the philoso- pher Michel Foucault, power is everywhere and inescapable. Untradi- tionally, power is not owned, and exertions of power are attempts to control other people’s possibilities to react, behave, or act. These attempts might or might not be successful. Objectives: The aim was to, from a Foucauldian perspective, explore and analyse the beliefs, experiences, and behaviours held and executed by Danish young adults with ADHD in relation to ADHD-medication treatment. Methods: A convenience sampling strategy was applied, including par- ticipants 18-29 years who had been prescribed medication for ADHD. Participants were interviewed either individually or in a focus group. A deductive analysis was conducted using concepts by Foucault. Results: A total of ten participants were interviewed whereof seven were women, the mean age was 23.9 years. Three discourses on ADHD were identified: sociological, biopsychosocial, and biomedical, which were falsified, present, and dominant, respectively. Difficulties to get non- pharmacological treatments and easiness to get medication lead to encouragement of medicine treatment, and hence strengthening the dominance of the biomedical discourse. The identified network of power was found to affect the participants and included: The three discourses on ADHD, governmentality of society, the public debate about ADHD in Denmark, external surveillance by doctors; and in the individual: inter- nalisation of the biomedical discourse as truth of ADHD-causality, and objectification of their self. The last resulting in self-monitoring and self- surveillance. Furthermore, medicine was used as control of oneself and to increase efficiency in order to fulfil requirements of the contemporary society. Overall, power was found to both subjectify and objectify ADHD- diagnosed, albeit there was also identification of some resistance to power. Discussion and conclusions: Decision-making on taking ADHD-medicine is complex and networks of power play a part in individuals’ decisions, also on a conscious level. These results show that a wider picture is accessible, that offer a diverse insight into the decision-making on medicine use compared to what on the surface can appear to be the choice of a single person. In addition, this stresses the importance of research within social pharmacy to include analyses that go beyond a traditional view of medi- cation procedures. “TO TAKE OR NOT TO TAKE”: FEARS ABOUT ANTIRETROVIRAL THERAPY AMONG PEOPLE LIVING WITH HIV/AIDS IN RUSSIA Victoria Dudina PhD, Darja Judina. St. Petersburg State University, Russia E-mail addresses: viktoria_dudina@mail.ru (V. Dudina), dartisimus@gmail.com (D. Judina). Introduction: The Russian Federation is one of 30 priority countries that UNAIDS has identified as needing focused action in order to scale up access to antiretroviral (ARV) therapy and achieve 80% HIV treatment coverage. Addressing the gap in access to HIV treatment is especially crucial given that the HIV epidemic continues to grow in Russia. ARVS have become more widely available in Russia in the past ten years; however, linkage to and retention in care remains a problem. A deeper understanding of fac- tors influencing the uptake of and adherence to HIV treatment of people living with HIV is important in order to address the HIV treatment gap. Objectives: The purpose of this research was to identify different types of fear related to starting and adhering to antiretroviral (ARV) therapy among people living with HIV in Russia. Methods: Data were collected from the Russian-language internet forum for people living with HIV (hivlife.info) which is a specialized forum for the discussion of challenges that people living with HIV experience. Qualita- tive data analysis was focused on the sections of the forum where users discussed health-related issues in order to examine the role of fear in decisions to start or continue ARVs. We developed a codebook to analyze the text and verified the coding through peer debriefing. Results: Fear influences decisions regarding HIV treatment in two ways: as a barrier or a motivator for engaging in treatment. Motivators for taking ARVs included fear of the illness itself and fear for well-being of significant others. Barriers to taking ARVs include fear of side effects, fear of therapy to be ineffective, fear that the appropriate medications will become unavai- lable, fear of changes to one’s lifestyle, fear to interact with the doctor, and fear to learn the negative information about one’s health. Discussion and conclusions: Different types of fear related to HIV are caused not only by the illness itself, but also by treatment and the con- ditions associated with treatment. Efforts to increase the uptake of and adherence to ARVs should take into account the fears of people living with HIV. Fear can be both a barrier and also a motivator for receiving HIV Abstracts / Research in Social and Administrative Pharmacy 13 (2017) e1ee15 e2